Here we review the current understanding of the role of the alternative pathway in PNH, including the emergence of C3‐mediated extravascular hemolysis in PNH patients on anti‐C5 therapies. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.